ELGX - Endologix, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
0.3101
+0.0568 (+22.42%)
At close: 4:00PM EDT

0.3900 +0.08 (25.77%)
Before hours: 8:15AM EDT

Stock chart is not supported by your current browser
Previous close0.2533
Open0.3373
Bid0.4180 x 1000
Ask0.4180 x 800
Day's range0.3020 - 0.4491
52-week range0.2300 - 7.2000
Volume37,071,130
Avg. volume1,235,009
Market cap5.945M
Beta (5Y monthly)0.74
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
Press releases
  • Business Wire

    Endologix Enters into an Agreement with Deerfield Partners to Take the Company Private

    Endologix Enters into an Agreement with Deerfield Partners to Take the Company Private

  • Endologix Announces Departure of CFO and Appointment of Interim CFO
    Business Wire

    Endologix Announces Departure of CFO and Appointment of Interim CFO

    Endologix, Inc. (Nasdaq: ELGX) ("Endologix" or the "Company"), a developer and marketer of innovative treatments for aortic disorders, today announced that Vaseem Mahboob, Chief Financial Officer (CFO), will be departing the Company effective July 1, 2020 to become CFO of a private global healthcare company. Cindy Pinto, Vice President, Financial Planning & Analysis, will assume the role of interim Chief Financial Officer in addition to her current responsibilities, and the Company has initiated a search process for a permanent successor that will include both internal and external candidates.

  • Endologix Issues Correction Notice for Ovation iX Abdominal Stent Graft System
    Business Wire

    Endologix Issues Correction Notice for Ovation iX Abdominal Stent Graft System

    Endologix® Inc. (Nasdaq: ELGX) ("Endologix" or the "Company"), a developer and marketer of innovative treatments for aortic disorders, today announced that a correction notice has been issued for the Ovation iX system, that identifies the root cause of polymer leaks. This voluntary action has been classified by the FDA as a Class 1 recall. No physical product removal of the product is planned or needed.

  • Endologix Announces Completion of Enrollment in the EVAS2 Confirmatory Clinical Study to Evaluate the Nellix EndoVascular Aneurysm Sealing System
    Business Wire

    Endologix Announces Completion of Enrollment in the EVAS2 Confirmatory Clinical Study to Evaluate the Nellix EndoVascular Aneurysm Sealing System

    Endologix® Inc. (Nasdaq: ELGX) ("Endologix" or the "Company"), a developer and marketer of innovative treatments for aortic disorders, today announced that it has completed enrollment in the EVAS2 Confirmatory Clinical Study to Evaluate the Nellix EndoVascular Aneurysm Sealing (EVAS) System.

  • Endologix Reports First Quarter 2020 Financial Results
    Business Wire

    Endologix Reports First Quarter 2020 Financial Results

    Endologix, Inc. (the "Company") (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced its financial results for the first quarter ended March 31, 2020. The Company’s financial results are preliminary and subject to any adjustments that may occur following the completion of the quarterly review of the Company’s financial statements by its independent auditor.

  • Endologix, Inc. to Announce First Quarter 2020 Financial Results on May 11, 2020
    Business Wire

    Endologix, Inc. to Announce First Quarter 2020 Financial Results on May 11, 2020

    Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter of fiscal year 2020 after the market close on Monday, May 11, 2020. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results.

  • Endologix Appoints Tim A. Benner as Chief Commercial Officer
    Business Wire

    Endologix Appoints Tim A. Benner as Chief Commercial Officer

    Endologix, Inc. (Nasdaq: ELGX) ("Endologix" or the "Company"), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed Tim A. Benner to succeed John Zehren as the Company’s Chief Commercial Officer, effective as of April 14, 2020.

  • Endologix Announces Preliminary Financial Results for First Quarter 2020
    Business Wire

    Endologix Announces Preliminary Financial Results for First Quarter 2020

    Endologix, Inc. (the "Company") (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that its preliminary unaudited revenue for the first quarter ended March 31, 2020 is expected to be approximately $28.5 million.

  • Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    Business Wire

    Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Endologix, Inc. (Nasdaq: ELGX) (the "Company"), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to two newly hired employees (the "Awardees"). The awards were approved by the Company’s Compensation Committee, which is comprised of independent directors, on March 25, 2020 as an inducement material to the Awardees’ entry into employment with the Company, as permitted under NASDAQ Listing Rule 5635(c)(4).

  • Endologix Adds Jane E. Kiernan to its Board of Directors
    Business Wire

    Endologix Adds Jane E. Kiernan to its Board of Directors

    Endologix, Inc. (Nasdaq: ELGX) ("Endologix" or the "Company"), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed Jane E. Kiernan to its board of directors, effective March 12, 2020. Ms. Kiernan has also been appointed to serve on the Audit Committee and the Nominating, Governance and Compliance Committee.

  • Endologix Receives FDA Approval for Alto Abdominal Stent Graft System
    Business Wire

    Endologix Receives FDA Approval for Alto Abdominal Stent Graft System

    Endologix® Inc. (Nasdaq: ELGX) ("Endologix" or the "Company"), a developer and marketer of innovative treatments for aortic disorders, today announced that it has received approval from the United States Food and Drug Administration (FDA) for the Alto™ Abdominal Stent Graft System (Alto).